Combination pharmacotherapy in psychotic depression: A systematic review and pairwise meta-analysis of randomized trials.

J Affect DisordJul 18, 2026 (epub)
Clinical ResearchPsychiatry

Gustavo Vazquez, Micaela Dines, Paloma Bamondez et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and pairwise meta-analysis evaluated the efficacy of combination pharmacotherapy in treating psychotic depression. Analyzing four randomized trials, the study found that combination therapy significantly improved clinical outcomes compared to non-combination treatment, with a risk ratio of 1.93 (95% CI 1.53-2.43).

Key findings

  • Combination pharmacotherapy showed a significantly higher likelihood of clinical improvement (RR 1.93, 95% CI 1.53-2.43).
  • Response-only analysis indicated an even greater effect (RR 2.03, 95% CI 1.51-2.75).
  • Remission-only outcomes also favored combination therapy (RR 1.78, 95% CI 1.27-2.49).

Why it matters

The findings support the use of combination pharmacotherapy in psychotic depression, a severe condition often resistant to standard treatments. This evidence aligns with current clinical guidelines, emphasizing the importance of effective treatment strategies.

Source

PubMed · PMID 42448052

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.